A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Haematology"
DOI: 10.1111/bjh.19320
Abstract: This phase II study evaluated time‐limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable… read more here.
Keywords: waldenstr macroglobulinaemia; ixazomib; phase study; study ibrutinib ... See more keywords
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2023011574
Abstract: Key Points • iFCR followed by 2 years of ibrutinib maintenance led to sustained deep remission in CLL irrespective of immunoglobulin heavy-chain variable region gene status.• Recurrent CLL lacked BTK mutations and retained sensitivity to… read more here.
Keywords: phase study; year follow; cll; five year ... See more keywords